Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|3 CitationsGLP-1 & Metabolic

Mazdutide (IBI362) Dosing Protocol: Dual GLP-1/Glucagon Guide

Also known as: IBI362, LY3305677, Oxyntomodulin Dual GLP-1/Glucagon Agonist

Dose Range
2 mgResearch range
0Typical research window: 2 mg3 mg

Studied in published research — not a medical recommendation. Primary protocol (GLORY-1 Phase 3 Standard Escalation Protocol (6 mg)): 2.0 mg (Wks 1–4) → 4.0 mg (Wks 5–8) → 6.0 mg maintenance (Wks 9–48), Once weekly.

Protocol at a Glance
How Often
Once weekly

Once weekly

A Typical Run
32–48 weeks

Research-reported range; the linked study used a different dose or units. Phase 3 GLORY-1 protocol; 4 mg and 6 mg maintenance cohorts achieved 12.1% to 14.8% body weight reduction at 48 weeks

How It's Taken
Vial

Subcutaneous injection

Evidence
Established

Human clinical trials or FDA-approved formulation exists

Half-Life & 72-Hour Clearance Shape
Not established

No verified human half-life on file for this compound

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

5 mg vial · 2 mL water · 0.5 mL syringe
Concentration: 2.5 mg in every mL (25 mcg per unit)
0u10u20u30u40u50u
Low end: 2 mg80 units

All U-100: 100 units = 1 mL. 2 doses in the vial at the low end.

Track the doses you run

Save Mazdutide to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

Phase 2/3 Clinical TrialsTier 1 — Human Phase 3 RCT / Approved
Pharmacological Class
Dual GLP-1 & Hepatic Glucagon Receptor Co-Agonist (Oxyntomodulin Class)
Administration Route
Under-the-skin injection (Subcutaneous injection)
2026 FDA & 503A Status
Approved by China NMPA (2025) for weight management; active global Phase 3 trials (GLORY-1/2). Not yet FDA-approved in the US or on the 503A bulk compounding list.
WADA Sport Status
Prohibited at All Times (WADA S0 Unapproved Substances & S2.2 Peptide Hormones, Growth Factors & Mimetics)
Evidence Tier
Tier 1 — Human Phase 3 RCT / Approved: Multi-center randomized controlled human clinical trials (Phase 3) and/or regulatory approval
What is a GLP-1 Agonist?

A molecule that mimics glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar, slows gastric emptying, and reduces appetite. Semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) are GLP-1 agonists. These are peptides, but they are marketed and prescribed as pharmaceutical drugs.

Bottom Line Up Front

Mazdutide (IBI362 / LY3305677) is a once-weekly mammalian oxyntomodulin analog that co-activates GLP-1 and Glucagon receptors. Phase 3 GLORY-1 (NEJM 2025) demonstrated up to 14.8% weight loss at 6 mg (and up to 18.6% at 9 mg in GLORY-2) alongside 73%–80% liver fat reduction.

Best evidence for

Obesity weight reduction (Phase 3 RCT), hepatic steatosis/MASH clearance, and uric acid/triglyceride lowering

Weakest evidence for

Head-to-head superiority over triple agonist Retatrutide at 12 mg

Pharma equivalent

Xinermei (Innovent / Eli Lilly — NMPA Approved 2025; Phase 3 Global)

Studies on file

3 (1 human)

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Mazdutide is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

Mazdutide is a long-acting synthetic peptide analog of mammalian oxyntomodulin originally discovered by Eli Lilly (LY3305677) and co-developed with Innovent Biologics (IBI362). Unlike pure GLP-1 mono-agonists (semaglutide) that rely primarily on caloric restriction via central satiety, Mazdutide balances GLP-1 receptor agonism with hepatic Glucagon receptor (GCGR) activation. This dual signaling simultaneously suppresses appetite while increasing resting energy expenditure, hepatic beta-oxidation, and lipolysis, while clearing liver fat and serum uric acid.

Mechanisms of Action

  • Agonizes GLP-1 receptors in the hypothalamus and pancreas to suppress appetite, slow gastric emptying, and enhance glucose-dependent insulin secretion
  • Activates hepatic Glucagon receptors (GCGR) to stimulate mitochondrial fatty acid oxidation, glycogenolysis modulation, and resting thermogenesis
  • Reduces hepatic de novo lipogenesis, achieving 73%–80% relative liver fat reduction in MASLD/MASH sub-studies
  • Fatty-acid acylation side chain binds serum albumin, extending elimination half-life to ~10–11 days for smooth once-weekly subcutaneous dosing

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
GLORY-1 Phase 3 Standard Escalation Protocol (6 mg)
reported protocol
2.0 mg (Wks 1–4) → 4.0 mg (Wks 5–8) → 6.0 mg maintenance (Wks 9–48)Once weekly32–48 weeksSubcutaneous injectionclinical trial
GLORY-2 High-Dose Escalation Protocol (9 mg)
reported protocol
3.0 mg (Wks 1–4) → 6.0 mg (Wks 5–8) → 9.0 mg maintenanceOnce weekly32–48 weeksSubcutaneous injectionclinical trial
Baseline & Mid-Cycle Biomarker Bloodwork Panel

Metabolic, Hepatic & Incretin Safety Biomarker Panel (Mazdutide)

Quantify visceral fat mobilization, insulin resistance reversal, hepatic steatosis (MASH) clearance, and pancreatic/renal safety during metabolic protocols.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

HbA1c & Fasting Insulin (HOMA-IR)

Day 0 + Wk 6–8

Why track at baseline: Measures baseline hyperinsulinemia and 90-day glycemic load prior to incretin or lipolytic initiation.

Week 6–8 check: Track rapid drop in Fasting Insulin (often 30%–50% reduction by Week 6–8) and normalizing HbA1c.

ALT, AST & GGT Liver Enzymes

Day 0 + Wk 6–8

Why track at baseline: Dual/triple agonists (Retatrutide, Mazdutide, Pemvidutide) mobilize 65%–80% of intrahepatic triglycerides.

Week 6–8 check: Confirm progressive reduction in ALT/AST (<25 U/L) as hepatic steatosis clears.

ApoB, Triglycerides & Advanced Lipid Panel

Day 0 + Wk 6–8

Why track at baseline: Quantifies atherogenic particle burden and VLDL triglyceride export before weight loss.

Week 6–8 check: Expect 20%–40% triglyceride drop and significant ApoB improvement alongside visceral fat loss.

Serum Lipase, Amylase & eGFR / Cystatin C

Day 0 + Wk 6–8

Why track at baseline: Essential safety screen for subclinical pancreatic inflammation and hydration/renal filtration.

Week 6–8 check: Ensure Lipase stays within reference range and eGFR remains stable with adequate electrolyte hydration.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

1 Human

In 610 adults with overweight or obesity randomized to Mazdutide 4 mg, 6 mg, or placebo for 48 weeks, Mazdutide achieved up to 14.8% weight loss along with marked reductions in waist circumference, blood pressure, LDL/triglycerides, ALT/AST, and serum uric acid.

Limitations: Conducted primarily in Chinese adult cohorts; Western global Phase 3 trials ongoing.

2025|New England Journal of Medicine
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Approved by China NMPA in 2025; remains investigational / non-FDA-approved in the United States
  • •Glucagon receptor co-agonism can modestly increase resting heart rate (+2 to +5 bpm)
  • •Transient gastrointestinal effects (nausea, diarrhea, decreased appetite) occur primarily during 4-week dose escalations
  • •Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or MEN2
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get Mazdutide, baseline labs & clinician oversight.

Compare all verified suppliers ↑
50% OFF AUTO-APPLIEDFrom $0.30/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR
FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Related Peptides

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.